News, Company News, Bio Shares, Issues, ABA Submissions, ABA Branch\nNews, Books, Meetings

Australasian Biotechnology, Volume 9 Number 2, May/June 1999,\npp.66-86, 101-123 News, Company News, Bio Shares, Issues, ABA\nSubmissions, ABA Branch News, Books, Meetings Code Number:AU99005 \nPRESIDENT'S REPORT In the last two issues of the Journal, I have set\nout to focus in the President's Report on identifying the activities\nthat the ABA Directors have been addressing on behalf of the ABA.\nSuccessful Cooperative Research Centres Senator Nick Minchin, Minister\nfor Industry, Science and Resources, announced in April the 26\nrecipients of the latest Cooperative Research Centre (CRC) funding\nround.\tWith the inclusion of the four new centres announced today,\nthere are now 67 CRC's across Australia. All centres fit within the six\ntargeted industry sectors - manufacturing technology, information and\ncommunications technology, mining and energy, agricultural and\nrural-based manufacturing, environment and medical science and\ntechnology. Directory of Biotech Organisation\tBiotechnology Australia\n The Australian Government's Department of Industry Science &\nResources recently re-launched its Biotechnology Section to provide an\ninteractive link between Government, research and commerce. World's\nFirst Treatment For Influenza Now Available In Australia The\nAustralian-developed world leading treatment for the influenza virus -\nRelenzaTM - is now available on prescription from pharmacists across\nthe country. Australians suffering the flu this winter will be first in\nthe world to have access to this revolutionary new product which will\nhelp combat the often devastating effects of the influenza virus. \nMajor Boost for R&D in Victoria The Government's budget allocation\nof $22.5 million to establish a Commonwealth Technology Port at\nMelbourne Dockland will provide a significant boost for research and\ndevelopment in Victoria, the Minister for Communications, the\nInformation Technology and the Arts, Senator Richard Alston, said\nrecently. "The park will focus on industrial research and is likely to\ngenerate $400 million in new investment over the next 10 years, with\nsignificant flow-on employment benefits for Victoria and the rest of\nthe nation well into the next century," Senator Alston said. "Funding\nfor this important four-year initiative is provided in full in this\nyear's budget - delivering in full the Government's A Vision for\nExcellence election promise." Natural Pathogens Show Promise for\nTermite Control The Forest and Wood Products Research and Development\nCorporation and CSIRO are collaborating to develop an environmentally\nfriendly alternative to termite control in urban areas. Scientists at\nCSIRO Entomology have identified strains of the naturally-occurring\nfungus Metarhizium which have the potential to control termites in\nbuildings and other built structures. Monsanto will wait for Studies\nof Disputed New Gene Technology (from the St. Louis Post-Dispatch23\nApril 99) Monsanto's "terminator technology" may not be terminated,\nbut neither will it be germinated soon because of the global furor it\nhas caused. St. Louis-based Monsanto Co. announced Thursday that it\nwould not market the controversial new gene technology until the\ncompletion of studies that examine the environmental, economic and\nsocial effects. Business Wire\tBusiness Wire, the global leader in\nnews distribution, and Mary Ann Liebert, Inc., the world's leading\nbiotechnology publisher, announced recently a strategic alliance to\nprovide the biotech and health care industries with a unparalleled\nmedia distribution and research capability. The new venture,\n"BioWire2K.com," will capitalize on the proven strengths of its\npartners. Business Wire's comprehensive distribution network to the\ninternational news media, global investment community, the Internet,\nonline services and databases will serve as the backbone of the new\nservice. New Advance in HIV Treatment Monitoring Bayer Diagnostics\nannounced recently that it has received the first Australian Government\nregulatory approval to supply a new generation of tests for measuring\nthe HIV virus in patients at risk of developing AIDS - which will\nensure a significant advance in patient treatment management. \nSex-change Barrumundi Cause Headaches Barramundi that prematurely\nchange their sex to become females are causing big headaches for\naquaculture farmers. All barrumundi are born as males and normally\nchange to females when they are about 6 years old. But young males\nselected to be breeding stock at the farms are changing prematurely,\nwhen they are only two years old. It isn't known why they change, but\nfarmers need an established stock of breeding males to improve the\nquality and output of the fish they sell. Developing A Vaccine Against\nGlandular Fever Known as the "kissing disease" glandular fever is one\nillness many teenagers are keen to avoid! But it may not be long before\nglandular fever is under the control of science. Researchers at the CRC\nfor Vaccine Technology (CRC-VT) are working towards a vaccine for\nEpstein-Barr virus (EBV), the virus responsible for glandular fever and\nother diseases like nasopharyngeal cancer. Address to Macquarie Bank \nExcepts From Dr. Michael Wooldridge, Minister For Health And Aged Care\n- 19 May 1999 "On capital market value, some seven out of the top 25\ncompanies in the world are health related. Ten years ago that figure\nwas just two, and in ten years' time, it will be 12 or 13 out of the\ntop 25 companies. In Australia the sheer size and scale of health is\noften not properly understood. Over the last decade we spend around 8%\nof GDP on health. US Launch for Australian Flower Technology \nFlorigene, a leading flower biotechnology company, launched its\nMoonshadowTM flower into the US market at the Super Floral Show in\nKansas City in June. MoonshadowTM is a new carnation flower with a\nunique violet colour. Florigene CEO, Peter Molloy, said the new\ncarnation followed many years of research and development and was the\nfirst of a range of new flowers incorporating the company's patented\nblue gene. Preliminary Study Shows The Utility Of Roche For Technology\nFor Screening HCV, HIV and HBV In Single Assay\tA preliminary study\nshows, for the first time, the utility of Roche's first-generation\nautomated PCR system to screen HCV, HIV and HBV blood donations in one\nsingle multi-plex assay. NRMRC Releases Draft Genetic Testing Document\n Genetic testing has the potential to greatly improve the health of all\nAustralians through better diagnosis and treatment, screening programs,\nand early prevention strategies. BioResearch Ireland Signs Research\nAgreement With US Company, Inhibitex BioResearch Ireland (BRI), the\nnational agency commercialising biotechnology, recently announced that\nit has signed an exclusive licensing and research agreement with\nInhibitex, Inc., A US biopharmaceutical company. The agreement focuses\non the prevention and treatment of infections by Staphylococcus aureus,\na bacterium which causes skin and wound infections and is a major cause\nof hospital acquired infections worldwide. In cases, where the pathogen\nhas developed resistance to antibiotics, it can cause life threatening\nsepticaemia. Forty percent of all deaths from hospital acquired\ninfections are caused by Staphylococcal infections. Business\nOpportunities in Malaysia A high level Trade and Investment mission,\nled by the Honourable Dato'Seri Rafidah Aziz, Minister of International\nTrade and Industry of Malaysia, will visit Australia from 1 - 8 August,\n1999 to promote and further strengthen the business and investment\nlinks between Australia and Malaysia. The mission members will include\nprivate sector representatives and senior officials from the Ministry\nof International Trade and Industry, Malaysian Industrial Development\nAuthority, Malaysian Trade and Development Corporation and State\nGovernments. Science Queensland '99 To Be Held In Brisbane The\nScientific Suppliers Association of Australia Inc. (SSAA) announces\nthat the Science Queensland '99 Exhibition will be held from the 9th -\n11th November 1999 in the Commerce Building, RNA, Brisbane. New\nLeadership for the Australian Proteome Analysis Facility The\nAustralian Proteome Analysis Facility (APAF), under newly appointed\nDirector Dr Gary Cobon, has its sights set on the future. APAF is a\nMajor National Research Facility set up in 1998 with Commonwealth funds\nof $7 million. It provides cutting edge proteomic research and\nanalytical services to the Australian scientific community. Westmead\nBiomedical Business Park Parramatta could become a world centre for\nthe biomedical industry, following an announcement by the GROW\nEmployment Council to conduct a $100,000 feasibility study into the\ndevelopment of a Biomedical Business Park near Westmead Hospital. The\nGROW study, to be jointly funded by the Federal Department of\nEmployment, Workplace Relations and Small Business and the NSW\nDepartment of State and Regional Development, was launched by Federal\nMP for Parramatta, Ross Cameron, at the University of Western Sydney in\nMarch 1999. Death of the Clever Country Australian technology\ncompanies are calling it "the death of the clever country". The Federal\nOpposition says it is "a national emergency". Venture capitalists warn\nit is at the point of "do or die". R&D in Australia is at the\ncrossroads, according to a report by Nick Tabakoff and Tony\nFeatherstone to be published in BRW on 2nd July. Agritech Mission to\nIsrael\tMr Phil Scanlan AM, Chief Executive Officer & Managing\nDirector, Bonlac Foods, will lead a large Australian business\ndelegation to Israel to attend the Agritech '99 Exhibition from 2 - 8\nSeptember. Canadian PM to Visit Australia Trade Mission Raises\nBiotechnology Profile Canadian Prime Minister Jean Chrétien will\nlead a Team Canada trade missio

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.